Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorROCHA, Lucila Soares da Silva
dc.contributor.authorRIECHELMANN, Rachel P.
dc.identifier.citationCLINICS, v.73, suppl.1, article ID UNSP e542s, 7p, 2018
dc.description.abstractPatients with unresectable metastatic colorectal cancer live for a median of three years when treated with standard therapies. While the evidence guiding cancer-directed treatment of this disease comes from phase III trials that have mostly enrolled patients with good performance status, some patients present with poor clinical conditions. The best treatment for these patients remains to be determined. We performed a systematic review of the treatment outcomes of patients with metastatic colorectal cancer and poor performance status, defined as Eastern Cooperative Oncology Group performance status >= 2. Eligible articles were prospective or retrospective studies or case reports published in English, Portuguese or Spanish. We searched PubMed, EMBASE, LILACS and the Cochrane Library from onset until October 2017 using specific keywords for each search. We found a total of 18 publications, mostly case reports and retrospective studies (14 articles). One was an uncontrolled prospective trial, two were observational studies and one was an individual patient meta-analysis. Although some studies suggested benefits in terms of symptomatic response with standard chemotherapy, with good safety profiles when dose-reduced regimens were administered, a true survival gain could not be demonstrated. The scientific evidence for treating metastatic colorectal cancer patients with poor performance status is scarce, and more studies evaluating treatment for this population are necessary since this condition is not uncommon in clinical practice, particularly in the public healthcare system and developing countries and among destitute populations.
dc.subjectMetastatic Colorectal Cancer
dc.subjectPoor Performance
dc.subject.otherrandomized controlled-trial
dc.subject.other1st-line treatment
dc.subject.otherpalliative chemotherapy
dc.subject.otherphase-3 trial
dc.subject.other2nd-line chemotherapy
dc.titleTreatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges
dc.rights.holderCopyright HOSPITAL CLINICAS, UNIV SAO PAULO
dc.subject.wosMedicine, General & Internal
hcfmusp.description.articlenumberUNSP e542s
hcfmusp.description.issuesuppl 1
hcfmusp.publisher.citySAO PAULO
hcfmusp.relation.referenceAnderson F, 1996, J PALLIAT CARE, V12, P5
hcfmusp.relation.referenceBenavides M, 2004, MED ONCOL, V21, P255, DOI 10.1385/MO:21:3:255
hcfmusp.relation.referenceBennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
hcfmusp.relation.referenceCarter GC, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0146-5
hcfmusp.relation.referenceChang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5
hcfmusp.relation.referenceCHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
hcfmusp.relation.referenceChibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344
hcfmusp.relation.referenceColorectal Canc Collaborative Grp, 2000, BMJ-BRIT MED J, V321, P531
hcfmusp.relation.referenceCunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5
hcfmusp.relation.referenceCunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2
hcfmusp.relation.referencede Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
hcfmusp.relation.referenceDouillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
hcfmusp.relation.referenceFalcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
hcfmusp.relation.referenceGallego R, 2006, EXPERT REV ANTICANC, V6, P795, DOI 10.1586/14737140.6-5.795
hcfmusp.relation.referenceGiantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
hcfmusp.relation.referenceGrande R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157751
hcfmusp.relation.referenceGrothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
hcfmusp.relation.referenceHo MY, 2016, CURR ONCOL, V23, P329, DOI 10.3747/co.23.3030
hcfmusp.relation.referenceHoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282
hcfmusp.relation.referenceJehn CF, 2014, EUR J CANCER, V50, P1269, DOI 10.1016/j.ejca.2014.01.005
hcfmusp.relation.referenceKohne CH, 2008, ONCOLOGIST, V13, P390, DOI 10.1634/theoncologist.2007-0043
hcfmusp.relation.referenceLe DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
hcfmusp.relation.referencePereira AAL, 2015, ACTA ONCOL, V54, P1737, DOI 10.3109/0284186X.2015.1044022
hcfmusp.relation.referenceLoupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108
hcfmusp.relation.referenceMassacesi C, 2002, AM J CLIN ONCOL-CANC, V25, P140, DOI 10.1097/00000421-200204000-00008
hcfmusp.relation.referenceMayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
hcfmusp.relation.referenceNaeim A, 2013, J GERIATR ONCOL, V4, P302, DOI 10.1016/j.jgo.2013.05.001
hcfmusp.relation.referenceNannini M, 2009, CANCER CHEMOTH PHARM, V64, P189, DOI 10.1007/s00280-009-0930-z
hcfmusp.relation.referenceNikolic-Tomasevic Z, 2000, J CHEMOTHERAPY, V12, P244, DOI 10.1179/joc.2000.12.3.244
hcfmusp.relation.referenceOverman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
hcfmusp.relation.referencePacetti P, 2015, SUPPORT CARE CANCER, V23, P3277, DOI 10.1007/s00520-015-2733-6
hcfmusp.relation.referencePrice TJ, 2012, ANN ONCOL, V23, P1531, DOI 10.1093/annonc/mdr488
hcfmusp.relation.referenceSargent DJ, 2009, J CLIN ONCOL, V27, P1948, DOI 10.1200/JCO.2008.20.2879
hcfmusp.relation.referenceSchnipper LE, 2012, J CLIN ONCOL, V30, P1715, DOI 10.1200/JCO.2012.42.8375
hcfmusp.relation.referenceSeifert H, 2015, GYNECOL ONCOL, V139, P216, DOI 10.1016/j.ygyno.2015.08.015
hcfmusp.relation.referenceSeymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3
hcfmusp.relation.referenceSgouros J, 2013, FORUM CLIN ONCOL, V4, P13
hcfmusp.relation.referenceShitara K, 2008, ONCOLOGY-BASEL, V74, P135, DOI 10.1159/000151360
hcfmusp.relation.referenceShitara K, 2010, CASE REP ONCOL, V3, P282, DOI 10.1159/000319474
hcfmusp.relation.referenceSorbye H, 2007, ACTA ONCOL, V46, P982, DOI 10.1080/02841860701261568
hcfmusp.relation.referenceSorbye H, 2009, CANCER, V115, P4679, DOI 10.1002/cncr.24527
hcfmusp.relation.referenceTabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
hcfmusp.relation.referenceTeixeira MC, 2015, CLIN COLORECTAL CANC, V14, P52, DOI 10.1016/j.clcc.2014.09.010
hcfmusp.relation.referenceTournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
hcfmusp.relation.referenceVan Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
hcfmusp.relation.referenceVan Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
hcfmusp.relation.referenceVenook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
hcfmusp.relation.referenceWheatley-Price P, 2014, CURR ONCOL, V21, P187, DOI 10.3747/co.21.1989
hcfmusp.relation.referenceWolmark N, 1998, J CLIN ONCOL, V16, P301
hcfmusp.relation.referenceZheng Z, 2014, CANCER MED-US, V3, P124, DOI 10.1002/cam4.176
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
art_ROCHA_Treatment_of_patients_with_metastatic_colorectal_cancer_and_2018.PDFpublishedVersion (English)329.11 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.